{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:44:16Z","timestamp":1747172656103,"version":"3.40.5"},"reference-count":10,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"unspecified","delay-in-days":180,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ASHE"],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:p>COVID-19 therapies were challenging to deploy due to evolving literature and conflicting guidelines. Antimicrobial stewardship can help optimize drug use. We conducted a survey to understand the role of stewardship and formulary restrictions during the pandemic. Restrictions for COVID-19 therapies were common and approval by infectious disease physicians often required.<\/jats:p>","DOI":"10.1017\/ash.2023.205","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T07:45:38Z","timestamp":1688111138000},"source":"Crossref","is-referenced-by-count":1,"title":["Antimicrobial stewardship and drug formulary restrictions during COVID-19: what is restricted and who decides?"],"prefix":"10.1017","volume":"3","author":[{"given":"Alfredo J.","family":"Mena Lora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6840-914X","authenticated-orcid":false,"given":"Scott","family":"Borgetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lelia H.","family":"Chaisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan C.","family":"Bleasdale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"key":"S2732494X2300205X_ref10","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab581"},{"key":"S2732494X2300205X_ref6","doi-asserted-by":"publisher","DOI":"10.1017\/ash.2023.146"},{"key":"S2732494X2300205X_ref2","unstructured":"2. Health Organization W. Guideline Therapeutics and COVID-19: Living Guideline; 2023. http:\/\/apps.who.int\/bookorders"},{"key":"S2732494X2300205X_ref1","unstructured":"1. National Institutes of Health. Coronavirus Disease 2019 (COVID-19) treatment guidelines. https:\/\/covid19treatmentguidelines.nih.gov\/. Accessed January 20, 2023."},{"key":"S2732494X2300205X_ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.54859"},{"key":"S2732494X2300205X_ref8","first-page":"2950","volume":"11","year":"2021","journal-title":"Cancer Discov"},{"key":"S2732494X2300205X_ref9","unstructured":"9. Berlin, G , Lapointe, M , Murphy, M , Wexler, J. Assessing the Lingering Impact of COVID-19 on the Nursing Workforce; 2022. https:\/\/www.mckinsey.com\/industries\/healthcare\/our-insights\/assessing-the-lingering-impact-of-covid-19-on-the-nursing-workforce. Accessed January 24, 2023."},{"key":"S2732494X2300205X_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.10.001"},{"key":"S2732494X2300205X_ref7","unstructured":"7. American Hospital Association. Remdesivir to be sold to hospitals, allocated through existing federal mechanism, 2020. https:\/\/www.aha.org\/special-bulletin\/2020-06-30-remdesivir-be-sold-hospitals-allocated-through-existing-federal. Published 2020. Accessed January 24, 2023."},{"key":"S2732494X2300205X_ref4","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2022.194"}],"container-title":["Antimicrobial Stewardship &amp; Healthcare Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2732494X2300205X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T07:45:43Z","timestamp":1688111143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2732494X2300205X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023]]}},"alternative-id":["S2732494X2300205X"],"URL":"https:\/\/doi.org\/10.1017\/ash.2023.205","relation":{},"ISSN":["2732-494X"],"issn-type":[{"type":"electronic","value":"2732-494X"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"e116"}}